Stay updated on DARA/ATRA Combo in Myeloma: Clinical Trial

Sign up to get notified when there's something new on the DARA/ATRA Combo in Myeloma: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the DARA/ATRA Combo in Myeloma: Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents the preclinical rationale for the clinical evaluation of ATRA and daratumumab in multiple myeloma patients, highlighting the synergy between these two agents in treating daratumumab-refractory disease.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:49.000Z thumbnail image
  4. Check
    5 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to provide a detailed description of eligibility criteria for clinical research, including examples such as a person's general health condition or prior treatments. The new text also directs users to read 'Learn About Studies' for general information about clinical research.
    Difference
    38%
    Check dated 2024-05-22T21:37:23.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:24:41.000Z thumbnail image

Stay in the know with updates to DARA/ATRA Combo in Myeloma: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the DARA/ATRA Combo in Myeloma: Clinical Trial page.